1983
DOI: 10.1016/0002-9378(83)90482-9
|View full text |Cite
|
Sign up to set email alerts
|

Role of androgens in menstrual disorders of nonhirsute and hirsute women, and the effect of glucocorticoid therapy on androgen levels in hirsute hyperandrogenic women

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

1983
1983
1993
1993

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 20 publications
(5 citation statements)
references
References 2 publications
0
5
0
Order By: Relevance
“…Indeed raised serum androgen levels in non-hirsute women with PCO have been reported (Lloyd et al, 1966;Yuen et al, 1983). It has also been implied in a number of other studies, but often aclear distinction between those with and without hirsutism is not made (Kandeel et al, 1980;Horrocks et al, 1983).…”
Section: Discussionmentioning
confidence: 94%
“…Indeed raised serum androgen levels in non-hirsute women with PCO have been reported (Lloyd et al, 1966;Yuen et al, 1983). It has also been implied in a number of other studies, but often aclear distinction between those with and without hirsutism is not made (Kandeel et al, 1980;Horrocks et al, 1983).…”
Section: Discussionmentioning
confidence: 94%
“…Early studies favoured an appetite stimulating effect of androgens causing obesity (Hosseinian et al, 1976;Wild et al, 1983) although no direct data have accumulated to support this hypothesis (Rosenfield et a/., 1984). Other studies have proposed hypothalamic defects (Kopelman et al, 1980) or an adrenal source (Ho Yuen & Mincey, 1983) to account for the androgen excess in obesity.…”
Section: Obesitymentioning
confidence: 99%
“…The latter combinations are often successful in inducing ovulation in women with hyperandrogenic anovulation or polycystic ovarian syndrome (PCO). [14][15][16] Bromocriptine remains the treatment of choice in hyperprolactinemic anovulation. Failure to respond or intolerance to these versatile first-line agents would be indications for exogenous gonadotropin therapy.…”
Section: Patient Selectionmentioning
confidence: 99%